Aikaterina Poulopoulou, Anna Sidiropoulou, Theopisti Sarmourli, Evaggelia Zachrou, Chrysi Michailidou, Charalampos Zarras, Eleni Vagdatli, Eleni Massa, Eleni Mouloudi, Athina Pyrpasopoulou, Georgios Meletis, Efthymia Protonotariou, Lemonia Skoura, Simeon Metallidis, Theodoros Karampatakis, Eleni Katsifa, Anna Nikopoulou, Alexandra Louka, Artemisia Rizou, Kostoula Arvaniti, Vassili Kouvelis, Andrew Borman, Emmanuel Roilides, Timoleon-Achilleas Vyzantiadis
{"title":"念珠菌:希腊北部的疫情爆发、监测和流行病学监测。","authors":"Aikaterina Poulopoulou, Anna Sidiropoulou, Theopisti Sarmourli, Evaggelia Zachrou, Chrysi Michailidou, Charalampos Zarras, Eleni Vagdatli, Eleni Massa, Eleni Mouloudi, Athina Pyrpasopoulou, Georgios Meletis, Efthymia Protonotariou, Lemonia Skoura, Simeon Metallidis, Theodoros Karampatakis, Eleni Katsifa, Anna Nikopoulou, Alexandra Louka, Artemisia Rizou, Kostoula Arvaniti, Vassili Kouvelis, Andrew Borman, Emmanuel Roilides, Timoleon-Achilleas Vyzantiadis","doi":"10.1093/mmy/myae062","DOIUrl":null,"url":null,"abstract":"<p><p>Candida auris is an emerging fungal pathogen associated with multi-drug resistance rates and widespread outbreaks in hospitals and healthcare units worldwide. Sequencing studies have revealed that different clonal lineages of the fungus seem to be prevalent among distinct geographical sites. The first case of C. auris in Northern Greece was reported in Thessaloniki in October 2022, almost 2 years after the first isolation in Greece (Athens 2019). The Mycology Laboratory of the Medical School of Aristotle University of Thessaloniki stands as the reference laboratory for fungal diseases in Northern Greece and a meticulous search for the yeast, in plenty of suspicious samples, has been run since 2019 in the Lab as well as a retrospective analysis of all its yeasts' collection, back to 2008, with negative results for the presence of C. auris. Here, are presented the findings concerning the outbreak and surveillance of C. auris in Northern Greece, mainly the region of Thessaloniki and the broader area of Macedonia, from October 2022 until August 2023. The isolates from Northern Greece continue to fall in Clade I and present with an almost equal and stable sensitivity profile until now.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232515/pdf/","citationCount":"0","resultStr":"{\"title\":\"Candida auris: Outbreak, surveillance and epidemiological monitoring in Northern Greece.\",\"authors\":\"Aikaterina Poulopoulou, Anna Sidiropoulou, Theopisti Sarmourli, Evaggelia Zachrou, Chrysi Michailidou, Charalampos Zarras, Eleni Vagdatli, Eleni Massa, Eleni Mouloudi, Athina Pyrpasopoulou, Georgios Meletis, Efthymia Protonotariou, Lemonia Skoura, Simeon Metallidis, Theodoros Karampatakis, Eleni Katsifa, Anna Nikopoulou, Alexandra Louka, Artemisia Rizou, Kostoula Arvaniti, Vassili Kouvelis, Andrew Borman, Emmanuel Roilides, Timoleon-Achilleas Vyzantiadis\",\"doi\":\"10.1093/mmy/myae062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Candida auris is an emerging fungal pathogen associated with multi-drug resistance rates and widespread outbreaks in hospitals and healthcare units worldwide. Sequencing studies have revealed that different clonal lineages of the fungus seem to be prevalent among distinct geographical sites. The first case of C. auris in Northern Greece was reported in Thessaloniki in October 2022, almost 2 years after the first isolation in Greece (Athens 2019). The Mycology Laboratory of the Medical School of Aristotle University of Thessaloniki stands as the reference laboratory for fungal diseases in Northern Greece and a meticulous search for the yeast, in plenty of suspicious samples, has been run since 2019 in the Lab as well as a retrospective analysis of all its yeasts' collection, back to 2008, with negative results for the presence of C. auris. Here, are presented the findings concerning the outbreak and surveillance of C. auris in Northern Greece, mainly the region of Thessaloniki and the broader area of Macedonia, from October 2022 until August 2023. The isolates from Northern Greece continue to fall in Clade I and present with an almost equal and stable sensitivity profile until now.</p>\",\"PeriodicalId\":18586,\"journal\":{\"name\":\"Medical mycology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232515/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical mycology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/mmy/myae062\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myae062","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
白色念珠菌(Candida auris)是一种新出现的真菌病原体,具有多重耐药性,在世界各地的医院和医疗机构中广泛爆发。测序研究显示,这种真菌的不同克隆系似乎在不同的地理位置流行。2022 年 10 月,希腊北部的塞萨洛尼基报告了首例 C. auris 病例,这距离希腊首次分离出 C. auris 病菌已过去近两年(雅典,2019 年)。塞萨洛尼基亚里士多德大学医学院的真菌学实验室是希腊北部真菌疾病的参考实验室,自2019年以来,该实验室在大量可疑样本中对酵母菌进行了细致的搜索,并对2008年以来收集的所有酵母菌进行了回顾性分析,结果均为阴性。这里介绍的是 2022 年 10 月至 2023 年 8 月期间希腊北部(主要是塞萨洛尼基大区和马其顿广大地区)弧菌疫情和监测结果。来自希腊北部的分离菌株仍属于第一支系,迄今为止其敏感性几乎相同且稳定。
Candida auris: Outbreak, surveillance and epidemiological monitoring in Northern Greece.
Candida auris is an emerging fungal pathogen associated with multi-drug resistance rates and widespread outbreaks in hospitals and healthcare units worldwide. Sequencing studies have revealed that different clonal lineages of the fungus seem to be prevalent among distinct geographical sites. The first case of C. auris in Northern Greece was reported in Thessaloniki in October 2022, almost 2 years after the first isolation in Greece (Athens 2019). The Mycology Laboratory of the Medical School of Aristotle University of Thessaloniki stands as the reference laboratory for fungal diseases in Northern Greece and a meticulous search for the yeast, in plenty of suspicious samples, has been run since 2019 in the Lab as well as a retrospective analysis of all its yeasts' collection, back to 2008, with negative results for the presence of C. auris. Here, are presented the findings concerning the outbreak and surveillance of C. auris in Northern Greece, mainly the region of Thessaloniki and the broader area of Macedonia, from October 2022 until August 2023. The isolates from Northern Greece continue to fall in Clade I and present with an almost equal and stable sensitivity profile until now.
期刊介绍:
Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.